OpenEvidence has announced the acquisition of Amaro, an AI-native advertising company founded by Kush Khosla and Sauren Khosla, and backed by Google Ventures and Greycroft. The deal strengthens OpenEvidence’s vision of delivering trusted, AI-driven clinical support to healthcare professionals, while also advancing its ad-supported business model.
OpenEvidence acquires AI-native ad company Amaro.
Amaro founded by Kush and Sauren Khosla, backed by GV and Greycroft.
Acquisition enhances AI-powered ad infrastructure for healthcare.
OpenEvidence powers 500,000+ clinical conversations daily.
Platform used by over 40% of U.S. physicians, growing 90,000 monthly.
Follows $210M Series B funding, valuing OpenEvidence at $3.5B.
Amaro was designed to help companies analyze and optimize advertising deployment through intelligent automation. By integrating Amaro’s technology and team, OpenEvidence enhances its advertising infrastructure to better serve healthcare professionals with sustainable, user-first solutions.
"I've had the privilege of backing both OpenEvidence and Amaro, and it's exciting to see them join forces," said Sangeen Zeb, general partner at GV. "The Khosla brothers have built an exceptional team at Amaro — combining resilience, vision, and technical excellence. This acquisition is a great fit, as Amaro's team and technology will help OpenEvidence accelerate its growth and further expand access to a trusted tool for clinicians."
Currently, OpenEvidence supports more than half a million clinical conversations daily with verified U.S. physicians, providing free access to the highest quality medical information. Its free-to-physician, ad-supported model ensures accessibility across practices of all sizes.
"OpenEvidence powers over half a million clinical conversations per day to verified American clinicians–for free. We believe every patient deserves to be seen by physicians with access to the highest quality information in the world, and our free-to-physician, ad-supported model enables every single practice in the country to leverage this technology, no matter the level of resources available to them," said Zachary Ziegler, cofounder of OpenEvidence. "The Amaro team moves fast, ships relentlessly, and shares our obsession with quality. This acquisition gives us a huge boost as we scale, and Amaro is a natural fit that accelerates our vision."
This acquisition builds on OpenEvidence’s rapid growth. The company recently closed a $210 million Series B funding round, reaching a $3.5 billion valuation. Today, over 40% of U.S. physicians rely on OpenEvidence daily for critical decision-making at the point of care, with the platform adding 90,000 new clinicians every month.
The addition of Amaro positions OpenEvidence to expand its dominance in medical search and AI, while reinforcing its mission to deliver trusted, accessible clinical intelligence.
TechIntelPro empowers B2B technology decision-makers with the latest industry trends, deep insights, leadership perspectives and actionable intelligence to drive both organizational and professional milestones—and thrive on the tech pulse.